This is a first-in-human, Phase 1, single-center, randomized, single-blind,
placebo-controlled, single dose-escalation study to evaluate the safety, tolerability, PK, PD
of SSS17 following oral administration in healthy subjects. Approximately 65 subjects (53
receiving active drug and 12 receiving placebo) will participate in this study.